Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial

Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(17)30279-6 ◽

2017 ◽

Vol 18 (6) ◽

pp. 779-791 ◽

Cited By ~ 197

Author(s):

Robert L Coleman ◽

Mark F Brady ◽

Thomas J Herzog ◽

Paul Sabbatini ◽

Deborah K Armstrong ◽

...

Keyword(s):

Ovarian Cancer ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Open Label ◽

Phase 3 ◽

Oncology Group Study ◽

Faculty Opinions recommendation of Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1166102.628092 ◽

2009 ◽

Author(s):

Jim Orr ◽

Fadi Abu Shahin

Keyword(s):

Ovarian Cancer ◽

Randomised Controlled Trial ◽

Controlled Trial ◽

Advanced Ovarian Cancer ◽

Open Label ◽

Phase 3 ◽

Dose Dense ◽

Randomised Controlled

Faculty Opinions recommendation of Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.737782327.793577733 ◽

2020 ◽

Author(s):

Diana English ◽

Andrea Buras

Keyword(s):

Ovarian Cancer ◽

Recurrent Ovarian Cancer ◽

Open Label ◽

Phase 3 ◽

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(21)00073-5 ◽

2021 ◽

Author(s):

Andrés Poveda ◽

Anne Floquet ◽

Jonathan A Ledermann ◽

Rebecca Asher ◽

Richard T Penson ◽

...

Keyword(s):

Ovarian Cancer ◽

Maintenance Therapy ◽

Final Analysis ◽

Phase 3 ◽

Double Blind ◽

Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial

The Lancet ◽

10.1016/s0140-6736(09)61157-0 ◽

2009 ◽

Vol 374 (9698) ◽

pp. 1331-1338 ◽

Cited By ~ 494

Author(s):

Noriyuki Katsumata ◽

Makoto Yasuda ◽

Fumiaki Takahashi ◽

Seiji Isonishi ◽

Toshiko Jobo ◽

...

Keyword(s):

Ovarian Cancer ◽

Randomised Controlled Trial ◽

Controlled Trial ◽

Advanced Ovarian Cancer ◽

Open Label ◽

Phase 3 ◽

Dose Dense ◽

Randomised Controlled

An open-label, multi-center, single-arm, phase 2 study of fluzoparib in patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian cancer

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-20-3546 ◽

2021 ◽

pp. clincanres.3546.2020

Author(s):

Ning Li ◽

Hualei Bu ◽

Jihong Liu ◽

Jianqing Zhu ◽

Qi Zhou ◽

...

Keyword(s):

Ovarian Cancer ◽

Recurrent Ovarian Cancer ◽

Phase 2 ◽

Open Label ◽

Platinum Sensitive ◽

Phase 2 Study

OPINION: A single-arm, open-label, phase IIIb study of olaparib maintenance monotherapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) and without germline BRCA mutations (non-gBRCAm)

Annals of Oncology ◽

10.1093/annonc/mdy285.207 ◽

2018 ◽

Vol 29 ◽

pp. viii356-viii357

Author(s):

A.M. Poveda ◽

R. Davidson ◽

C. Blakeley ◽

A. Milner

Keyword(s):

Ovarian Cancer ◽

Open Label ◽

Brca Mutations ◽

Platinum Sensitive ◽

Phase Iiib ◽

The MEK Inhibitor in Low-Grade Serous Ovarian Cancer (MILO)/ENGOT-ov11 study: A multinational, randomized, open-label phase 3 study of binimetinib (MEK162) versus physician’s choice chemotherapy in patients with recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.tps5618 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. TPS5618-TPS5618

Author(s):

Bradley J. Monk ◽

Rachel N. Grisham ◽

Christian Marth ◽

Susana N. Banerjee ◽

Felix Hilpert ◽

...

Keyword(s):

Ovarian Cancer ◽

Fallopian Tube ◽

Mek Inhibitor ◽

Low Grade ◽

Serous Ovarian Cancer ◽

Open Label ◽

Phase 3 ◽

The MILO (MEK inhibitor in low-grade serous ovarian cancer)/ENGOT-ov11 study: A multinational, randomized, open-label phase 3 study of binimetinib (MEK162) versus physician’s choice chemotherapy in patients with recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.tps5610 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. TPS5610-TPS5610 ◽

Cited By ~ 4

Author(s):

Bradley J. Monk ◽

Rachel N. Grisham ◽

Christian Marth ◽

Susana N. Banerjee ◽

Felix Hilpert ◽

...

Keyword(s):

Ovarian Cancer ◽

Fallopian Tube ◽

Mek Inhibitor ◽

Low Grade ◽

Serous Ovarian Cancer ◽

Open Label ◽

Phase 3 ◽

Nanoparticle micellar formulation of paclitaxel in combination with carboplatin for women with recurrent platinum sensitive ovarian cancer (OAS07-OVA): Overall survival results of a phase 3 randomized trial.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.5560 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 5560-5560 ◽

Cited By ~ 1

Author(s):

Nina Heldring ◽

Helena Bjermo ◽

Arija Brize ◽

Alla Sergeevua Lisyanskaya ◽

Ignace Vergote

Keyword(s):

Ovarian Cancer ◽

Overall Survival ◽

Randomized Trial ◽

Phase 3 ◽